{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-002321","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2022-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.515677+00:00","generated_at":"2026-06-27T15:54:09.931414+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bolt Biotherapeutics amends supply agreement with EirGenix for trastuzumab biosimilar; up to $2M milestones","bullets":["Amended supply agreement with EirGenix for bulk drug substance EG12014, a trastuzumab biosimilar used in BDC-1001 HER2 Boltbody ISAC.","Requires joint steering committee, revised forecasting/order terms, and pricing adjustments based on production scale.","Company to make up to $2.0M in milestone payments upon regulatory achievements for HER2 Boltbody ISAC.","Agreement remains effective as long as Bolt or affiliates continue development/commercialization of the ISAC product."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-002321","json":"https://secwatch.observer/filing/0001564590-22-002321.json","markdown":"https://secwatch.observer/filing/0001564590-22-002321.md","text":"https://secwatch.observer/filing/0001564590-22-002321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000156459022002321/0001564590-22-002321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000156459022002321/bolt-8k_20220125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T15:54:09.931414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}